Epocrates: PDA medical software

Recent Updates

November 11, 2009

FDA Update - Tamiflu Use in Pediatrics
The FDA recently amended the Emergency Use Authorization (EUA) for Tamiflu (oseltamivir) in infants less than 1 year of age for the treatment and prophylaxis of influenza A 2009 H1N1 virus. Treatment doses should be based on weight rather than age, whenever possible. Prophylaxis is not recommended for infants less than 3 months old, due to limited data on use in this age group, unless the exposure is significant and the risk of severe illness is considered high. Tamiflu should be used only in full-term infants, since there are insufficient data to recommend a specific dose for premature infants. FDA Update - Tamiflu Use in Pediatrics »

November 04, 2009

MedWatch Safety Alert for Byetta
The FDA issued an emergency use authorization (EUA) for the investigational intravenous neuraminidase inhibitor, peramivir, for use in children and adults with known or suspected infection with influenza A 2009 H1N1 virus. This unapproved product should be used only for hospitalized patients who are unresponsive to or unable to take oral or inhaled antiviral therapies, or when IV therapy is deemed clinically appropriate. MedWatch Safety Alert for Byetta »

October 28, 2009

New Drug Monograph for Peramivir
The FDA issued an emergency use authorization (EUA) for the investigational intravenous neuraminidase inhibitor, peramivir, for use in children and adults with known or suspected infection with influenza A 2009 H1N1 virus. This unapproved product should be used only for hospitalized patients who are unresponsive to or unable to take oral or inhaled antiviral therapies, or when IV therapy is deemed clinically appropriate. New Drug Monograph for Peramivir »